PILL240920C10000
- 0.05
- 0.000.00%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares Newsroom
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
Johnson & Johnson Analyst Ratings
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Bicara, MBX Bio Lead Gainers as Biotech Trio Makes Trading Debut
How do you view the recent "hawkish" stance of the Bank of Japan executives? Goldman Sachs: The next interest rate hike may still have to wait until January next year.
Goldman Sachs believes that when evaluating the timing of interest rate hikes, it is important to consider financial market stability and inflation trends. The bank predicts that January next year will be the best time to determine whether Japan's inflation will rebound, and based on this, determine that Japan will raise interest rates in January. However, if there is significant turmoil in the financial markets, the timing of the rate hike may become uncertain.
Unpacking the Latest Options Trading Trends in Johnson & Johnson
JNJ Submits Application to EMA for Nipocalimab for Generalized Myasthenia Gravis
How To Earn $500 A Month From Johnson & Johnson Stock
Metals in Tampons: FDA Initiates New Safety Measures and Testing
Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
16 New GLP-1 Weight-loss Drugs Could Be Launched by 2029: Report